🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Children's Cancer Group, China clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Children's Cancer Group, China as lead sponsor. Synced 26 Sep 2026
8Current trials
4Recruiting now
10Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Children's Cancer Group, China is the lead sponsor of 8 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 2/3. The drugs named most often in its trials are Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone, Prednisone,Vincristine, Cyclophosphamide and Brentuximab Vedotin. The most-studied condition is Mature B-cell Non-Hodgkin Lymphoma.

ClinicalTrials.gov trials by status

  • Recruiting450%
  • Active, closed450%

Trials by phase

  • Phase 2/3338%
  • Phase 3338%
  • Phase 4113%
  • Observational113%
01

Clinical trials sponsored by Children's Cancer Group, China

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
NCT06563245 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Child, Adolescent
Phase 2/3 Recruiting 2024-09 China
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
NCT05681260 · ClinicalTrials.gov ↗ · T-cell Lymphoblastic Lymphoma
Phase 3 Recruiting 2023-02 China
Shanghai Epidemiology Study for Adolescents and Children with Cancer
NCT02959086 · ClinicalTrials.gov ↗ · Childhood Cancer
Observational Recruiting 2002-01 China
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
NCT07168980 · ClinicalTrials.gov ↗ · Mature B-cell Non-Hodgkin Lymphoma
Phase 2/3 Recruiting 2025-07 China
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
NCT04726501 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma
Phase 4 Active, closed 2018-04 China
BNHL-2015 for Children or Adolescents in China
NCT02405676 · ClinicalTrials.gov ↗ · Mature B-cell Non-Hodgkin Lymphoma
Phase 2/3 Active, closed 2015-01 China
CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
NCT04881838 · ClinicalTrials.gov ↗ · Pediatric Anaplastic Large Cell Lymphoma
Phase 3 Active, closed 2021-03 China
LBL-2016 for Children or Adolescents in China
NCT02845882 · ClinicalTrials.gov ↗ · Lymphoblastic Lymphoma
Phase 3 Active, closed 2016-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Children's Cancer Group, China trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Children's Cancer Group, China trials

10 conditions
Mature B-cell Non-Hodgkin Lymphoma2Hodgkin Lymphoma1Classical Hodgkin Lymphoma1Child1Adolescent1Young Adult1Pediatric Anaplastic Large Cell Lymphoma1Lymphoblastic Lymphoma1T-cell Lymphoblastic Lymphoma1Childhood Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China84

A trial with sites in more than one country appears in each of those registers.

05

Questions about Children's Cancer Group, China trials

How many clinical trials does Children's Cancer Group, China sponsor?

Children's Cancer Group, China is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Children's Cancer Group, China trials recruiting?

Yes. 4 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Children's Cancer Group, China testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone (2), Prednisone,Vincristine, Cyclophosphamide (2), Brentuximab Vedotin (1), Cyclophosphamide (1) and Dacarbazine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.